Literature DB >> 26965540

Predicting Persistent Left Ventricular Dysfunction Following Myocardial Infarction: The PREDICTS Study.

Gabriel C Brooks1, Byron K Lee1, Rajni Rao1, Feng Lin2, Daniel P Morin3, Steven L Zweibel4, Alfred E Buxton5, Mark J Pletcher2, Eric Vittinghoff2, Jeffrey E Olgin6.   

Abstract

BACKGROUND: Persistent severe left ventricular (LV) systolic dysfunction after myocardial infarction (MI) is associated with increased mortality and is a class I indication for implantation of a cardioverter-defibrillator.
OBJECTIVES: This study developed models and assessed independent predictors of LV recovery to >35% and ≥50% after 90-day follow-up in patients presenting with acute MI and severe LV dysfunction.
METHODS: Our multicenter prospective observational study enrolled participants with ejection fraction (EF) of ≤35% at the time of MI (n = 231). Predictors for EF recovery to >35% and ≥50% were identified after multivariate modeling and validated in a separate cohort (n = 236).
RESULTS: In the PREDICTS (PREDiction of ICd Treatment Study) study, 43% of patients had persistent EF ≤35%, 31% had an EF of 36% to 49%, and 26% had an EF ≥50%. The model that best predicted recovery of EF to >35% included EF at presentation, length of stay, prior MI, lateral wall motion abnormality at presentation, and peak troponin. The model that best predicted recovery of EF to ≥50% included EF at presentation, peak troponin, prior MI, and presentation with ventricular fibrillation or cardiac arrest. After predictors were transformed into point scores, the lowest point scores predicted a 9% and 4% probability of EF recovery to >35% and ≥50%, respectively, whereas profiles with the highest point scores predicted an 87% and 49% probability of EF recovery to >35% and ≥50%, respectively.
CONCLUSIONS: In patients with severe systolic dysfunction following acute MI with an EF ≤35%, 57% had EF recovery to >35%. A model using clinical variables present at the time of MI can help predict EF recovery.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  heart failure; remodeling; risk assessment; ventricular ejection fraction

Mesh:

Year:  2016        PMID: 26965540      PMCID: PMC4854198          DOI: 10.1016/j.jacc.2015.12.042

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  16 in total

1.  Declining length of stay for patients hospitalized with AMI: impact on mortality and readmissions.

Authors:  Jane S Saczynski; Darleen Lessard; Frederick A Spencer; Jerry H Gurwitz; Joel M Gore; Jorge Yarzebski; Robert J Goldberg
Journal:  Am J Med       Date:  2010-11       Impact factor: 4.965

2.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

3.  Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction.

Authors:  Sean D Pokorney; Amy L Miller; Anita Y Chen; Laine Thomas; Gregg C Fonarow; James A de Lemos; Sana M Al-Khatib; Eric D Peterson; Tracy Y Wang
Journal:  JAMA       Date:  2015 Jun 23-30       Impact factor: 56.272

4.  Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study.

Authors:  S D Solomon; R J Glynn; S Greaves; U Ajani; J L Rouleau; F Menapace; J M Arnold; C Hennekens; M A Pfeffer
Journal:  Ann Intern Med       Date:  2001-03-20       Impact factor: 25.391

5.  Clinical reminders to providers of patients with reduced left ventricular ejection fraction increase defibrillator referral: a randomized trial.

Authors:  Anurag Gupta; Parisa Gholami; Mintu P Turakhia; Karen Friday; Paul A Heidenreich
Journal:  Circ Heart Fail       Date:  2013-12-06       Impact factor: 8.790

6.  Relation of plasma brain natriuretic peptide levels on admission for ST-elevation myocardial infarction to left ventricular end-diastolic volume six months later measured by both echocardiography and cardiac magnetic resonance.

Authors:  Ana Garcia-Alvarez; Marta Sitges; Victoria Delgado; Jose Ortiz; Bárbara Vidal; Silvia Poyatos; Teresa Maria de Caralt; Magda Heras; Xavier Bosch; Manel Azqueta; Carles Pare; Josep Brugada
Journal:  Am J Cardiol       Date:  2009-10-01       Impact factor: 2.778

7.  Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction.

Authors:  H A Katus; A Remppis; T Scheffold; K W Diederich; W Kuebler
Journal:  Am J Cardiol       Date:  1991-06-15       Impact factor: 2.778

8.  Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

Authors:  Stanley Chia; Fred Senatore; O Christopher Raffel; Hang Lee; Frans J Th Wackers; Ik-Kyung Jang
Journal:  JACC Cardiovasc Interv       Date:  2008-08       Impact factor: 11.195

9.  Predictors of recovery of left ventricular systolic dysfunction after acute myocardial infarction: from the korean acute myocardial infarction registry and korean myocardial infarction registry.

Authors:  Pyung Chun Oh; In Suck Choi; Taehoon Ahn; Jeonggeun Moon; Yeonjeong Park; Jong Goo Seo; Soon Yong Suh; Youngkeun Ahn; Myung Ho Jeong
Journal:  Korean Circ J       Date:  2013-08-31       Impact factor: 3.243

10.  The optimal time of B-type natriuretic peptide sampling associated with post-myocardial infarction remodelling after primary percutaneous coronary intervention.

Authors:  Hyunmin Choi; Byung-Su Yoo; Joon-Hyung Doh; Hee-Jeong Yooh; Min-Soo Ahn; Jang-Young Kim; Seung-Hwan Lee; Junghan Yoon
Journal:  Cardiovasc J Afr       Date:  2013-06       Impact factor: 1.167

View more
  24 in total

Review 1.  Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure.

Authors:  Shweta R Motiwala; Hanna K Gaggin
Journal:  Curr Heart Fail Rep       Date:  2016-10

Review 2.  Recent Updates in the Role of Wearable Cardioverter Defibrillator for Prevention of Sudden Cardiac Death.

Authors:  Irene Kirolos; David Jones; Kirstin Hesterberg; Charles Yarn; Rami N Khouzam; Yehoshua C Levine
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-08-08

3.  Delivery of a matrix metalloproteinase-responsive hydrogel releasing TIMP-3 after myocardial infarction: effects on left ventricular remodeling.

Authors:  Brendan P Purcell; Shayne C Barlow; Paige E Perreault; Lisa Freeburg; Heather Doviak; Julia Jacobs; Abigail Hoenes; Kia N Zellars; Aarif Y Khakoo; TaeWeon Lee; Jason A Burdick; Francis G Spinale
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-07-06       Impact factor: 4.733

4.  Stem-cell therapy in ST-segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double-blind randomized trial.

Authors:  José C Nicolau; Remo H M Furtado; Suzana A Silva; Carlos E Rochitte; Anis Rassi; João B M C Moraes; Edgard Quintella; Costantino R Costantini; Adrian P M Korman; Marco A Mattos; Hélio J Castello; Adriano Caixeta; Hans F R Dohmann; Antonio C C de Carvalho
Journal:  Clin Cardiol       Date:  2018-03-22       Impact factor: 2.882

Review 5.  [Wearable defibrillator : Current evidence].

Authors:  David Duncker; Christian Veltmann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-10-24

6.  Wearable Cardioverter-Defibrillator after Myocardial Infarction.

Authors:  Jeffrey E Olgin; Mark J Pletcher; Eric Vittinghoff; Jerzy Wranicz; Rajesh Malik; Daniel P Morin; Steven Zweibel; Alfred E Buxton; Claude S Elayi; Eugene H Chung; Eric Rashba; Martin Borggrefe; Trisha F Hue; Carol Maguire; Feng Lin; Joel A Simon; Stephen Hulley; Byron K Lee
Journal:  N Engl J Med       Date:  2018-09-27       Impact factor: 91.245

Review 7.  Who Should Receive a Wearable Defibrillator Vest at Hospital Discharge?

Authors:  Sergey Kachur; Daniel P Morin
Journal:  Curr Cardiol Rep       Date:  2019-09-07       Impact factor: 2.931

8.  Meta-analysis of short- and long-term efficacy of mononuclear cell transplantation in patients with myocardial infarction.

Authors:  Dan Yang; Connor Galen O'Brien; Gentaro Ikeda; Jay H Traverse; Doris A Taylor; Timothy D Henry; Roberto Bolli; Phillip C Yang
Journal:  Am Heart J       Date:  2019-11-11       Impact factor: 4.749

9.  Comparison of the Outcome of Patients Protected by the Wearable Cardioverter Defibrillator (WCD) for <90 Wear Days versus ≥90 Wear Days.

Authors:  Tobias C Dreher; Ibrahim El-Battrawy; Susanne RÖger; Stephanie L Rosenkaimer; Stefan Gerhards; JÜrgen Kuschyk; Martin Borggrefe; Ibrahim Akin
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

Review 10.  High-Sensitivity Troponin as a Biomarker in Heart Rhythm Disease.

Authors:  Cian P McCarthy; Omair Yousuf; Alvaro Alonso; Elizabeth Selvin; Hugh Calkins; John W McEvoy
Journal:  Am J Cardiol       Date:  2017-02-09       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.